UK signs deal for 60m doses of potential coronavirus vaccine

UK signs deal for 60m doses of potential coronavirus vaccine

Britain has signed a deal for the supply of up to 60 million doses of a potential coronavirus vaccine developed by Sanofi and GlaxoSmithKline (GSK).

Human clinical studies of the vaccine will begin in September followed by a phase 3 study in December.

The government has now signed deals for four different types of potential coronavirus vaccines and a total of 250 million doses.

If the Sanofi/GSK treatment proves successful, the UK could begin vaccinating priority groups such as frontline health and social care workers and those at increased risk from coronavirus.

The vaccinations would take place as early as the first half of next year, the Department for Business, Energy & Industrial Strategy (BEIS) said.









































What are the COVID-19 vaccine contenders?









Financial terms of the agreement between the government and Sanofi/GSK were not disclosed.

No vaccine has yet been approved to treat or prevent COVID-19.

Business Secretary Alok Sharma said: "Our scientists and researchers are racing to find a safe and effective vaccine at a speed and scale never seen before.

"While this progress is truly remarkable, the fact remains that there are